Pentixapharm Launches Rights Issue to Fund PANDA Phase 3 and U.S. Expansion

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN OR ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL

Pentixapharm Launches Rights Issue to Fund PANDA Phase 3 and U.S. Expansion

Major shareholder Eckert Wagniskapital commits to fully exercise its subscription rights

Berlin, July 1, 2026 – Pentixapharm Holding AG, Berlin, (ISIN DE000A40AEG0, WKN A40AEG) today announced that its Management Board, with the approval of the Supervisory Board, has resolved on a capital increase with subscription rights, structured as a rights issue to existing shareholders.

The Company plans to increase its share capital against cash contributions from currently EUR 24,795,477.00 by up to EUR 11,020,212.00 to up to EUR 35,815,689.00 through the issuance of up to 11,020,212 new registered no-par value shares. The capital increase will be carried out by making partial use of the Company’s Authorized Capital.

The new shares will carry full dividend rights as from January 1, 2026 and are intended to be offered to existing shareholders by way of indirect subscription rights. The subscription ratio will be 9:4, meaning that nine existing shares entitle their holder to subscribe for four new shares. The subscription price per new share is EUR 1.85. This represents a discount of approximately 21% to the Xetra closing price of the share on June 30, 2026.

The subscription period is expected to begin on July 7, 2026 and to end on July 21, 2026. Shareholders are also expected to have the opportunity to subscribe, at the subscription price, for additional new shares in excess of their statutory subscription rights by way of an oversubscription offer. Any new shares not subscribed for may be offered to selected qualified investors in a private placement at a price at least equal to the subscription price. The rights issue is being accompanied by BankM AG.

Pentixapharm’s major shareholder, Eckert Wagniskapital und Frühphasenfinanzierung GmbH, which holds just under 36% of the Company’s shares, has committed to fully exercise its subscription rights in the rights offering.

Dr. Dirk Pleimes, CEO of Pentixapharm, commented: “This rights issue is intended to provide Pentixapharm with additional financial flexibility to execute on our most important near-term value drivers. Our priority is to advance PANDA, our Phase 3 program evaluating [⁶⁸Ga]Ga-PentixaFor in primary aldosteronism, while continuing to build the clinical, regulatory and manufacturing foundation for our broader CXCR4 platform. The commitment of Eckert Wagniskapital to fully exercise its subscription rights underscores the continued support for our strategy.”

Assuming full placement of all new shares, Pentixapharm would receive gross issue proceeds of up to approximately EUR 20.4 million. After deduction of estimated transaction costs, net proceeds are expected to amount to approximately EUR 19.8 million, assuming full subscription.

The Company intends to use the net proceeds primarily to finance key steps of the PANDA Phase 3 study, as well as the Company’s further corporate development and expansion in the U.S. market. The PANDA Phase 3 study evaluates [⁶⁸Ga]Ga-PentixaFor, the Company’s lead CXCR4-targeted diagnostic program, in patients with difficult-to-control hypertension due to underlying primary aldosteronism. The registrational trial is intended to further develop a novel imaging-based approach to patient subtyping designed to support treatment decisions between surgical and medical management.

A further portion of the net proceeds is intended to be used to continue preparing clinical development activities and to strengthen the Company’s manufacturing and supply infrastructure. These measures are intended to support the late-stage clinical development of the Company’s programs and further build the foundation for potential future commercialization.

In addition, Pentixapharm intends to use proceeds to further develop its CXCR4-based theranostic platform, including PentixaTher in hematologic oncology indications. Finally, the proceeds are intended to strengthen the Company’s equity base and to fund general corporate purposes and working capital beyond the first quarter of 2027.

Further details of the rights issue will be set out in the subscription offer, which is expected to be published in the electronic German Federal Gazette on July 3, 2026.

No securities prospectus will be published for the public offering of the new shares or for their admission to trading on the regulated market of the Frankfurt Stock Exchange, with simultaneous admission to the sub-segment of the regulated market with additional post-admission obligations, the Prime Standard. In accordance with Regulation (EU) 2017/1129, Pentixapharm will publish a document containing the information required under Annex IX to Regulation (EU) 2017/1129. The Annex IX document is expected to be available on the Company’s website in the Investors section as from July 3, 2026.

About Pentixapharm

Pentixapharm Holding AG (Frankfurt Prime Standard: PTP) is a clinical-stage biotechnology company headquartered in Berlin developing innovative nuclear medicine approaches to help physicians detect, characterize, and treat serious diseases with greater precision. The company’s compounds are designed to deliver medical radioisotopes specifically to defined biological targets  - either for high-resolution molecular imaging or for targeted radioligand therapy.

Pentixapharm's pipeline is built on CXCR4 targeting, a receptor with strong scientific validation across multiple disease areas, and encompasses diagnostic and therapeutic programs in endocrine, cardiovascular, and oncological indications. The lead program, [⁶⁸Ga]Ga-PentixaFor, is entering into a registrational Phase 3 study (PANDA) for non-invasive subtyping of primary aldosteronism. The PENTHERA program advances the CXCR4-directed theragnostic platform into Phase I/II in oncology. Complementing the CXCR4 platform, Pentixapharm is also developing a next-generation antibody platform targeting CD24, an emerging immune checkpoint in difficult-to-treat cancers.

Further Information:  www.pentixapharm.com

Contact

Pentixapharm Holding AG

Investor Relations

Robert-Rössle-Straße 10

13125 Berlin

Deutschland

E-Mail: ir@pentixapharm.com

Important Notice

This announcement does not constitute an offer to sell or a solicitation of an offer to purchase or subscribe for any securities. Any public offering will be made solely on the basis of the subscription offer to be published and the Annex IX document.

This announcement is not intended for publication, distribution or release in or into the United States of America, Australia, Canada, Japan or any other jurisdiction where such publication, distribution or release would be unlawful.

The new shares have not been and will not be registered under the U.S. Securities Act of 1933, as amended, and may not be offered or sold in the United States of America or to, or for the account or benefit of, U.S. persons absent registration under, or an applicable exemption from the registration requirements of, the Securities Act. There will be no public offering of the shares in the United States of America.